CAMBRIDGE, Mass., Aug. 2, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the pricing of an underwritten registered public offering of 22,000,000 shares of its common stock at a public offering price of $8.00 per share. All of the shares are being sold by Idenix. The offering is expected to close on August 7, 2012, subject to customary closing conditions.
